Immunocore Holdings (IMCR) Operating Leases (2019 - 2026)

Immunocore Holdings has reported Operating Leases for 8 years, with the latest figure at $42.0 million in Q1 2026.

• Quarterly Operating Leases fell 1.04% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (down 1.04% YoY) and the FY2025 annual result came in at $41.6 million, up 3.47% from the prior year.
• Operating Leases climbed to $42.0 million in Q1 2026 per IMCR's latest filing, from $41.6 million in the prior quarter.
• Over five years, Operating Leases peaked at $44.4 million in Q2 2025 and troughed at $31.8 million in Q3 2022.
• A 5-year average of $38.6 million and a median of $40.2 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2025: Operating Leases retreated 3.06% in 2022, then rose 27.48% in 2025.
• Over 5 years, Operating Leases stood at $33.1 million in 2022, then advanced by 7.48% to $35.6 million in 2023, then grew by 12.78% to $40.2 million in 2024, then increased by 3.47% to $41.6 million in 2025, then grew by 1.12% to $42.0 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $42.0 million, $41.6 million, and $43.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.